Cinislioglu AE, Demirdogen SO, Cinislioglu N, et al. - Men with BPH diagnosed with COVID-19 show significant increases in PSA levels during the active period of the disease. This may lead to false evaluations when measuring PSA values used in the diagnosis, differential diagnosis, and follow-up of prostate diseases in the acute period of infection and in the early period after infection treatment and may, in turn, affect the diagnosis and treatment steps of prostate diseases in these patients.

• Patients who had had a PSA check at least 3 months, but no more than 6 months, prior to diagnosis of acute COVID-19 infection, were examined retrospectively for their PSA (Kit: Immunoassay Program- Cycle 18, Siemens Atellica IM Analyzer) levels.

• Serum PSA levels of 1.58±1.09 ng/ml, 4.34±3.78 ng/ml and 2.09±2.70 ng/ml were recorded in 91 patients during the pre-COVID-19 period, the COVID-19 period and the post-COVID-19 period, respectively.

• Overall, there was statistically significantly higher serum PSA level during active COVID-19 infection than the PSA levels measured according to the pre-COVID-19 period and the post-COVID-19 period.